NBP606 clinical trials
Also written NBP606.
How each study uses NBP606 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- NBP606
- 3
Studies by the year they started
3 studies that test it; most in 2013 (1)
| Year | Studies |
|---|---|
| 2013 | 1 |
| 2014 | 1 |
| 2015 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 3
- 3
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 3 · Other 0
Studies
Open first, then newest update. How each study uses NBP606 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 3
- Immunogenicity and Safety Study of NBP606 in Healthy InfantsCompletedPhase 3SK Chemicals Co., Ltd.NCT02201030Written as NBP606How we know
- Immunogenicity and Safety Study of NBP606 in Healthy ToddlersCompletedPhase 3SK Chemicals Co., Ltd.NCT02927444Written as NBP606How we know
- Study Immunogenicity and Safety of 13-valent Pneumococcal Conjugate VaccineCompletedPhase 3SK Chemicals Co., Ltd.NCT02079207Written as NBP606How we know